Transcriptome Analysis of the Peripheral Blood in CIDP

Identification of the Mechanisms of Action of Intravenous Immunoglobulins in CIDP by Analysis of the Genetic Expression Profile in Blood Mononuclear Cells

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02404298

Acronym

PHARMACOPID

Enrollment

Registered

2015-03-31

Start date

2015-02-28

Completion date

2018-09-30

Last updated

2018-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autoimmune Diseases, Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Clarkson Syndrome, Muscular Autoimmune Disorders

Keywords

Transcriptome analysis, peripheral blood, chronic inflammatory demyelinating polyradiculoneuropathy, auto immune diseases, IVIg

Brief summary

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an immune-mediated disorder of peripheral nerves. Intravenous immunoglobulins (IVIg) are a first line therapy for CIDP. The investigators used a transcriptomic approach to compare the gene expression profiles in the peripheral blood of patients having a CIDP or autoimmune diseases, before and after IVIg treatment, in order to identify their mechanism of action in this condition, to lead to a better understanding of CIDP pathophysiology, and potentially determine factors associated with the response to the treatment.

Detailed description

We study the change of the: * gene profile on transcriptome analysis of peripheral blood * T cell repertory * igG dosage * immunological profile Before IVIG (T1 time) and and 3 weeks after IVIg treatment (T2 time). On a population of patients having: CIDP, autoimmune muscular disease, Clarkson syndrome, or autoimmune diseases. We also search for polymorphism of FCgammareceptor, TKPC et CASP3 genes in CIDP patients

Interventions

DRUGIVIg

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

: * Age ≥ 18 years old * Obtained informed consent * Patient having a definite or probable CIDP according to EFNS/PNS criteria or atypical CIDP corresponding to patients having the EFNS/PNS clinical criteria and at least two EFNS/PNS supportive criteria * Or * Patient having a muscular autoimmune disease, or a Clarkson syndrome or other autoimmune disease * Currently treated by IVIG

Exclusion criteria

: * pregnancy * breastfeeding

Design outcomes

Primary

Measure	Time frame	Description
Gene expression profile	3 weeks	Change of the gene expression profile of a peripheral blood sample collected. just before IVIg administration (T1), and 3 weeks after IVIg treatment (T2)

Secondary

Measure	Time frame	Description
Gene expression profile in each lymphocytary sub-group	3 weeks	Change of the gene expression profile of a peripheral blood sample collected. just before IVIg administration (T1), and 3 weeks after IVIg treatment (T2), in each lymphocytary sub-group : CD3+CD4+, CD3+CD8+, CD4+FoxP3+, CD4+CD25+
IgG	3 weeks	To measure IgG in a peripheral blood sample at T1 and T2 time

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026